COMMUNIQUÉS West-GlobeNewswire
 
      -   
  Lumere Appoints Scott A. Falk, MD, to Advisory Council20/02/2018
-   
  Bone Therapeutics SA strengthens Board with the appointment of Jean Stéphenne as Chairman20/02/2018
-   
  Bone Therapeutics SA annonce le renforcement de son Conseil d'administration avec la nomination de Jean Stéphenne en tant que Président20/02/2018
-   
  Konica Minolta Healthcare’s Exa Enterprise Imaging Delivers Intelligent Analytics to Radiology Departments20/02/2018
-   
  Orano Med and RadioMedix announce dosing of first patients in AlphaMedix™ Phase 1 clinical trial20/02/2018
-   
  Hands On Technology, Inc. Partners with ABILITY Network to Help Physical Therapy Providers Simplify Revenue Cycle Management20/02/2018
-   
  swyMed Unveils the DOT Mini to Provide Dependable Connectivity for Video Telemedicine Encounters20/02/2018
-   
  U.S. Preventive Medicine and Solera Health Partner to Deliver Comprehensive Health Coaching and Nurse Based Chronic Condition Care Management Services20/02/2018
-   
  Shire to Present Data at 2018 AAAAI/WAO Joint Congress Demonstrating Commitment to Ongoing Research and Innovation in Rare Immune Conditions20/02/2018
-   
  IGC Announces Third Quarter Financial Results Advances Hyalolex to Commercialization Stage20/02/2018
-   
  INSYS Therapeutics to Present at RBC Healthcare Conference20/02/2018
-   
  NSS Labs Announces 2018 Data Center Intrusion Prevention Systems Group Test Results20/02/2018
-   
  OrthoPediatrics Corp. to Participate in Canaccord Genuity’s Musculoskeletal Conference20/02/2018
-   
  Matrix Medical Network Completes Acquisition of HealthFair20/02/2018
-   
  Lexington Begins HeartSentry Clinical Trial20/02/2018
-   
  Predictive Technology Group, Inc. (PRED) Announces Completion of Genotyping in Two Clinical Trials of ARTGuide™20/02/2018
-   
  Burcon Congratulates Protein Industries Canada20/02/2018
-   
  In Midst of Flu Epidemic, Teladoc Provides Relief for Overburdened Health System20/02/2018
-   
  Xenon Pharmaceuticals Advances Second Proprietary Epilepsy Product into the Clinic with Initiation of XEN901 Phase 1 Clinical Trial20/02/2018
Pages